Navigation Links
Actavis Launches Oxymorphone Hydrochloride Extended-Release Tablets, CII in the U.S.
Date:7/20/2011

MORRISTOWN, N.J., July 20, 2011 /PRNewswire/ -- Actavis, an international generic pharmaceutical company, today announced that it has begun shipping Oxymorphone Hydrochloride Extended-Release Tablets, CII 7.5mg and 15mg, a generic equivalent of Opana ER®.

The 7.5mg and 15mg strength of Opana ER had U.S. total sales of approximately $21.9 million for the 12 months ending March 31, 2011, according to IMS Health.  

Commenting on the launch, Michael Perfetto, Vice President, Sales & Marketing of Actavis, Inc. in the United States said:

"Oxymorphone Extended-Release Tablets offer significant value to our customers and patients.  This launch exemplifies Actavis' focus, commitment and capability in bringing complex controlled-release products to our customers."

Please see prescribing information at www.actavis.us/oxymorphone.

About Actavis:

Actavis Inc. is the U.S. distributor of the product and the U.S. subsidiary of Actavis Group hf.  Approximately one third of Actavis Group hf's sales are generated in North America, Actavis' single largest market. Based in Morristown, NJ, Actavis Inc. has U.S. manufacturing facilities in Elizabeth, NJ and Lincolnton, NC. Actavis also has research and development facilities in Elizabeth, NJ, Owings Mills, MD and Sunrise, FL.

Actavis Group hf is one of the world's leading generic pharmaceutical companies specializing in the development, manufacture and sale of generic pharmaceuticals.  The company has operations in 40 countries, with more than 10,500 employees.

Opana ER ® is a trademark owned by a party other than Actavis.

Information in this press release may contain forward-looking statements with respect to the financial condition, results of operations and businesses of Actavis.  By their nature, forward-looking statements and forecasts involve risk and uncertainty because they relate to events and depend on circumstances that will occur in the future. There are a number of factors that could cause actual results and developments to differ materially from that expressed or implied by these forward-looking statements. These factors include, among other things, exchange rate fluctuations, the risk that research and development will not yield new products that achieve commercial success, the impact of competition, price controls and price reductions, the risk of loss or expiration of patents or trade marks, difficulties of obtaining and maintaining governmental approvals for products, the risk of substantial product liability claims, exposure to environmental liability.


'/>"/>
SOURCE Actavis Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Actavis Hails U.S. Supreme Court Decision in Labeling Cases
2. Actavis Receives FDA Approval of Zolpidem Tartrate Extended-Release Tablets USP, 12.5 mg CIV in the U.S.
3. Actavis Receives FDA Approval of Donepezil Hydrochloride Tablets in the U.S.
4. Actavis Receives Approval of Valacyclovir Hydrochloride Tablets in the U.S.
5. Actavis Receives Approval of Pantoprazole Sodium Delayed-Release Tablets, USP in the U.S.
6. Actavis Encourages Consumers to Return Fentanyl Transdermal System 25 mcg/h
7. Actavis Inc. Issues a Voluntary Recall of 18 Lots of Fentanyl Transdermal System 25 mcg/h
8. Actavis Receives Approval of Zolpidem Tartrate Extended-Release Tablets, USP 6.25mg CIV in the U.S. with 180-Day Marketing Exclusivity
9. Actavis Receives Approval of Losartan Potassium Tablets, USP in the U.S.
10. Actavis Receives FDA Approval of Atomoxetine HCl Capsules
11. Actavis Receives Approval of Bupropion HCl SR 100mg and 200mg in the U.S.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... , June 24, 2016 ... Market by Type (Standard Pen Needles, Safety Pen Needles), ... (Insulin, GLP-1, Growth Hormone), Mode of Purchase (Retail, Non-Retail) ... MarketsandMarkets, This report studies the market for the forecast ... to reach USD 2.81 Billion by 2021 from USD ...
(Date:6/24/2016)... , Belgium , June 24, ... VNRX), today announced the appointment of Dr. ... Directors as a Non-Executive Director, effective June 23, ... Audit, Compensation and Nominations and Governance Committees.  As ... Futcher will provide independent expertise and strategic counsel ...
(Date:6/23/2016)...  MedSource announced today that it has selected ... of choice.  This latest decision demonstrates MedSource,s commitment ... clients by offering a state-of-the-art electronic data capture ... as the EDC platform of choice in exchange ... has long been a preferred EDC platform by ...
Breaking Medicine Technology:
(Date:6/26/2016)... NC (PRWEB) , ... June 26, 2016 , ... Brent Kasmer, a legally blind and ... to be personalized through a fitness app. The fitness app plans to fix the two ... currently only offer a one size fits all type program , They don’t ...
(Date:6/25/2016)... ... ... Austin residents seeking Mohs surgery services, can now turn to Dr. Jessica Scruggs ... for medical and surgical dermatology. , Dr. Dorsey brings specialization to include Mohs surgery, ... Micrographic Surgery completed by Dr. Dorsey was under the direction of Glenn Goldstein, MD, ...
(Date:6/25/2016)... (PRWEB) , ... June 25, 2016 , ... First ... United States, named Dr. Sesan Ogunleye, as the Medical Director of its new Mesquite-Samuell ... facility Medical Director of our new Mesquite location,” said Dr. James M. Muzzarelli, Executive ...
(Date:6/25/2016)... ... ... On Friday, June 10, Van Mitchell, Secretary of the Maryland Department of Health ... of their exemplary accomplishments in worksite health promotion. , The Wellness at Work Awards ... at the BWI Marriott in Linthicum Heights. iHire was one of 42 businesses to ...
(Date:6/24/2016)... Marne, Michigan (PRWEB) , ... June 24, 2016 , ... ... To deal with these feelings, many turn to unhealthy avenues, such as drug or ... Center of Marne, Michigan, has released tools for healthy coping following a traumatic event. ...
Breaking Medicine News(10 mins):